Katja Sockel, Martin Bornhaeuser, Eva Mischak-Weissinger, Rudolf Trenschel, Martin Wermke, Christian Unzicker, Guido Kobbe, Jürgen Finke, Ulrich Germing, Brigitte Mohr, Jochen Greiner, Dietrich Beelen, Christian Thiede, Gerhard Ehninger, Uwe Platzbecker. Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial. haematol [Internet]. 2012Sep.5 [cited 2024Nov.22];97(9):e34-e35. Available from: https://haematologica.org/article/view/6423